Metraipolis › archive › dc_fd1667718fb5

Cost-effectiveness of pasireotide as second-line therapy for adult acromegaly patients from the perspective of the Brazilian Unified Health System — Europe PMC PMID:42621460

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42621460
DOI
10.3389/fendo.2026.1771580
License (as archived)
solo-consultazione
Archived
2026-10-17T02:07:32.421Z
SHA-256 of the archived text
6e7ef9bc1a447dd136d6f3ae8ef6cee3bbc8bb2d61b744df3632dc3ea2f86ff5
Stable URL of this page
https://metraipolis.com/documento/dc_fd1667718fb5

How to cite

Cost-effectiveness of pasireotide as second-line therapy for adult acromegaly patients from the perspective of the Brazilian Unified Health System — Europe PMC PMID:42621460 — Europe PMC (en), https://europepmc.org/article/MED/42621460 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fd1667718fb5 (Metraipolis archive dc_fd1667718fb5, sha256 6e7ef9bc1a447dd136d6f3ae8ef6cee3bbc8bb2d61b744df3632dc3ea2f86ff5)
BibTeX
@misc{dcfd1667718fb5,
  title = {Cost-effectiveness of pasireotide as second-line therapy for adult acromegaly patients from the perspective of the Brazilian Unified Health System — Europe PMC PMID:42621460},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42621460},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fd1667718fb5; sha256 6e7ef9bc1a447dd136d6f3ae8ef6cee3bbc8bb2d61b744df3632dc3ea2f86ff5},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42621460. Agents can read the archived copy with the MCP tool read_document.